Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


11 Items
Title  Creator  Group name  Publishing year 
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer Orhan et al. EquipeCTCS 2024-05-01
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib Velazquez et al. EquipeMY 2023
In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2 du Manoir et al. EquipeCTCS 2022-07
SLUG and Truncated TAL1 Reduce Glioblastoma Stem Cell Growth Downstream of Notch1 and Define Distinct Vascular Subpopulations in Glioblastoma Multiforme Guelfi et al. EquipeCTCS 2021-10-27
MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis Kantar et al. EquipeAM 12/2021
Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells Fonti et al. EquipeCTCS Sep 01, 2019
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer Bourillon et al. EquipeELC 2019-10-01
Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53 Arena et al. EquipeCTCS Feb 15, 2018
TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion Chevalier et al. EquipeMY Feb 22, 2016
Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells Bach et al. EquipeELC Sep 29, 2015
Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse du Manoir et al. EquipeCTCS Mar 2014
11 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés